A multicentre, open label, dose escalation, Phase 1 study in patients with unresectable or metastatic melanoma receiving IMP321 (LAG-3Ig fusion protein) as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab.

Trial Profile

A multicentre, open label, dose escalation, Phase 1 study in patients with unresectable or metastatic melanoma receiving IMP321 (LAG-3Ig fusion protein) as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2017

At a glance

  • Drugs IMP 321 (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; First in man
  • Acronyms TACTI-mel
  • Sponsors Prima Biomed
  • Most Recent Events

    • 26 Jun 2017 According to a Prima BioMed media release, company expects to present data set from the first two cohorts at the World Immunotherapy Congress and SITC, Society for Immunotherapy of Cancer, National Harbor in 2017.
    • 26 Jun 2017 According to a Prima BioMed media release, company has completed recruitment of the first two cohorts of six patients and has now commenced recruitment of the third cohort. Data from all three cohorts is expected in H1, 2018.
    • 18 Apr 2017 The company has received approval to begin dosing in the third cohort of this trial, according to Prima BioMed media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top